We are proud to announce the signing of a Master Service Agreement with Kidswell Bio Corporation and Chiome Bioscience Inc., marking the beginning of a strategic collaboration to develop new biosimilar drugs.
As a Taiwan-based CDMO with deep expertise in biologics development and manufacturing, Mycenax is honored to support this initiative—starting with cell line development for new biosimilars at our state-of-the-art facility.
This partnership builds on the June 2024 alliance between Kidswell and Chiome and aligns with their recent selection on May 2025—alongside Alfresa Holdings—for Japan’s MHLW subsidy program aimed at strengthening Japanese domestic biosimilar manufacturing capabilities.
Together, we aim to:
-Build robust biosimilar cell lines
-Establish scalable biosimilar process
-Support Japan’s biomanufacturing infrastructure
-Explore global opportunities for biosimilars
We look forward to contributing to a more resilient and innovative biotech ecosystem through this meaningful collaboration.
About Mycenax
Mycenax takes the CDMO brand positioning of "big D and medium M" with "Innovative development abilities (D) and Adequate manufacturing capacity (M)" to provides one-stop services for the development and manufacture of traditional biologics and novel biological drugs. At its core, Mycenax is committed to the development and production of biological drugs, from the R&D phase to cGMP manufacturing plants to drug commercialization. Mycenax, as an international CDMO company, continuously invests in product development innovations and technology platform optimizations in order to provide customers with comprehensive and streamlined CDMO services. Mycenax Biotech currently has a capital of 2.07 billion NTD.
Stock code: Mycenax Biotech (4726).
Company website: http://www.mycenax.com
Press Contact:
Liru Yeh
Email: liru.yeh@mycenax.com
We are proud to announce the signing of a Master Service Agreement with Kidswell Bio Corporation and Chiome Bioscience Inc., marking the beginning of a strategic collaboration to develop new biosimilar drugs.
As a Taiwan-based CDMO with deep expertise in biologics development and manufacturing, Mycenax is honored to support this initiative—starting with cell line development for new biosimilars at our state-of-the-art facility.
This partnership builds on the June 2024 alliance between Kidswell and Chiome and aligns with their recent selection on May 2025—alongside Alfresa Holdings—for Japan’s MHLW subsidy program aimed at strengthening Japanese domestic biosimilar manufacturing capabilities.
Together, we aim to:
-Build robust biosimilar cell lines
-Establish scalable biosimilar process
-Support Japan’s biomanufacturing infrastructure
-Explore global opportunities for biosimilars
We look forward to contributing to a more resilient and innovative biotech ecosystem through this meaningful collaboration.
About Mycenax
Mycenax takes the CDMO brand positioning of "big D and medium M" with "Innovative development abilities (D) and Adequate manufacturing capacity (M)" to provides one-stop services for the development and manufacture of traditional biologics and novel biological drugs. At its core, Mycenax is committed to the development and production of biological drugs, from the R&D phase to cGMP manufacturing plants to drug commercialization. Mycenax, as an international CDMO company, continuously invests in product development innovations and technology platform optimizations in order to provide customers with comprehensive and streamlined CDMO services. Mycenax Biotech currently has a capital of 2.07 billion NTD.
Stock code: Mycenax Biotech (4726).
Company website: http://www.mycenax.com
Press Contact:
Liru Yeh
Email: liru.yeh@mycenax.com